|
|
Post by mytakeonit on Jan 17, 2019 0:34:48 GMT -5
I think Mike C is going nuts tonight ... his original intention for the 1,000 is not what is being construed.
Too bad ... so sad
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 17, 2019 0:39:44 GMT -5
I think Mike C is going nuts tonight ... his original intention for the 1,000 is not what is being construed. Too bad ... so sad Please elaborate. |
|
|
|
Post by mytakeonit on Jan 17, 2019 1:10:02 GMT -5
As I said earlier, Mike C had intended it for the 65,000 people who don't have insurance and have to pay for their Afrezza with cash. If the 1,000 who do sign up isn't part of that 65,000 people, then it is going to the wrong people.
But, if this $120 per month can cover the cost of producing Afrezza ... then, maybe this is the way to go to get rid of expiring inventory. Help the people and not just dump product. Break even on production costs and also have the public experience the workings of Afrezza.
Maybe we will be doing something better than paying for advertising. Interesting.
|
|
|
|
Post by goyocafe on Jan 17, 2019 1:16:04 GMT -5
How about Edelman in the video saying how the sound of inhaler reminds him about smoking weed ... now we are talking! š°š Well, he said Doritos remind him of weed but it was in the context that relates to how the inhaler sounds and his ātechniqueā. At least thatās what I heard... š I got so excited after watching the video in this thread, I did not realize there is a separate video thread, my bad ...š I thought it was more his comment about the ease of inhaling sounding familiar and not the sound of the inhaler. |
|
|
|
Post by babaoriley on Jan 17, 2019 1:51:29 GMT -5
I can imagine...all the large pharma in the hearings on their high prices...and then Mannkind gets a mention by Congress...How is it..this 1% company has what appears to better outcomes..can sell insulin at $4 a day..I mean..lower hypos..no shot..free inhaler..no weight gain..why is your slower in and out insulins..so expensive? Ohhhhh! The reality of the $4 price is that it is not sustainable. If it garners Mannkind some short term press, great. But it is a promotional price that will cost the company money to run. I hope the pr benefits outweigh the costs. I would not be so sure, goyo, we have a lot of excess capacity. |
|
|
|
Post by travis1953 on Jan 17, 2019 2:07:14 GMT -5
As I said earlier, Mike C had intended it for the 65,000 people who don't have insurance and have to pay for their Afrezza with cash. If the 1,000 who do sign up isn't part of that 65,000 people, then it is going to the wrong people. But, if this $120 per month can cover the cost of producing Afrezza ... then, maybe this is the way to go to get rid of expiring inventory. Help the people and not just dump product. Break even on production costs and also have the public experience the workings of Afrezza. Maybe we will be doing something better than paying for advertising. Interesting. If the program were directed strictly at 65,000 without insurance, then there should have been some sort of screening process to rule out those who can afford afrezza. Lilly offers humalog free but you have to meet the financial criteria.
www.lillycares.com/aboutlillycares.aspx
I suspect it's more of a marketing method to spread afrezza awareness among the diabetic community.
Will they advertise the program or will they promote it through just the sales reps?
|
|
|
|
Post by itellthefuture777 on Jan 17, 2019 3:40:39 GMT -5
As I said earlier, Mike C had intended it for the 65,000 people who don't have insurance and have to pay for their Afrezza with cash. If the 1,000 who do sign up isn't part of that 65,000 people, then it is going to the wrong people. But, if this $120 per month can cover the cost of producing Afrezza ... then, maybe this is the way to go to get rid of expiring inventory. Help the people and not just dump product. Break even on production costs and also have the public experience the workings of Afrezza. Maybe we will be doing something better than paying for advertising. Interesting. If the program were directed strictly at 65,000 without insurance, then there should have been some sort of screening process to rule out those who can afford afrezza. Lilly offers humalog freeĀ but you have to meet the financial criteria.
www.lillycares.com/aboutlillycares.aspx
I suspect it's more of aĀ marketing methodĀ to spread afrezza awareness among the diabetic community.
Will they advertise the program or will they promote it through just the sales reps?
Streamlined..if you have a Precription...first 1000..out of 30,000,000..then..there is the $15 card..and remember..Afrezza is non-inferior..fastest in..fastest out..many more clinical benefits to the patient..should be the higheat priced insulin based on outcomes..but...Mannkind..listen to the patient needs..while the rest remained unmoved...priceless |
|
|
|
Post by sportsrancho on Jan 17, 2019 7:09:42 GMT -5
MNKD - Getting a lot of questions from people about news after the bell regarding a new set of marketing initiatives announced by the company. I will be blunt - I have no idea about the unit economics associated with the initiatives, but sounds very good to me. I have no idea about ARPU - āas low as $4ā generally means very few at $4, and for 12 months, then the step up? And what cost basis? No idea. I used to work on such marketing initiatives way back when whilst a manager in the British Telecom mobile unit, and one thing I learned is that there are the numbers and there is disruption. This sounds a bit disruptive. And the stock market usually likes disruption...Will also get the weekly script watchers into a bit of a tiff, as now they will be sweating it all quarter into the quarterly calls. Could see some short covering...Overall - brilliant move (even if I still want the CEO to forego his 2018 bonus). #MNKD . 44m Michael Kovacocy Michael KovacocyI really see no negatives from this, only positives. At a minimum/worst case it will allow for volume to be sold at cost which will greatly enhance capacity utilization and bring down per unit costs and expand margins in the existing mainline Afrezza business. It is not mutually exclusive with the existing route to market, so a nice channel to open up. Also should dovetail nicely into the ad campaign. There is no way that ARPU will be even close to $4 as the headline states. If one assumes a higher rate and puts a conservative 10% long term penetration of the relevant market, that is very material additional revenue and potentially direct margin. The indirect margin expansion across all Afrezza sales from capacity utilization should also be material. |
|
|
|
Post by pat on Jan 17, 2019 7:12:53 GMT -5
I donāt know actual numbers but MC has said repeatedly marginal cost of production very little. Guessing far below $120 so each prescription will help defray high fixed costs.
Bottom line - the more people using this revolutionary product, the more buzz and quicker wide spread adoption.
MC and team more than earning their money in my book.
I continue to buy and wait.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 17, 2019 8:49:03 GMT -5
Two enquires/opinions.
1. Since Symphony uses rx numbers from pharmacies, will these new program rxs be excluded from the weekly Friday numbers?
2. Would be nice if MNKD, once the 1000 people are enrolled to put out a PR. Something like 1000 people were enrolled in under 1 week.
|
|
|
|
Post by travis1953 on Jan 17, 2019 13:02:23 GMT -5
Technically, the scripts will be filled by Eagle Pharmacy, so I imagine they should show up in the script numbers. I wonder how much Eagle is getting paid to handle the filling and shipping.
|
|
|
|
Post by jonny80s on Jan 17, 2019 13:25:05 GMT -5
No insurance... likely hood of going to Doctor and getting a script.......
|
|
|
|
Post by longliner on Jan 17, 2019 13:48:08 GMT -5
No insurance... likely hood of going to Doctor and getting a script....... So go to the neighborhood clinic....... |
|
|
|
Post by sportsrancho on Jan 17, 2019 14:32:41 GMT -5
I donāt believe that pharmacy sells itās data to symphony, or thatās what Iāve been told. So the scripts wonāt show up.
Other than that I keep getting questions about why Mannkind has not advertised this program on their Facebook page?
|
|
|
|
Post by od on Jan 17, 2019 15:16:31 GMT -5
From a retired Pharma executive (me) -- I am uncomfortable with the lack of transparency -- what is pricing for patient 1001? What can patients 1 - 1000 expect to pay after year one. I also don't like the January deadline; the first 1000, should be the first 1000. If this is a marketing/awareness program, it's creepy using un/underinsured patient positioning as the fly-paper.
|
|
